Phase II Study of Bevacizumab Combined With Capecitabine and Oxaliplatin (CAPOX) in Patients With Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater.

Trial Profile

Phase II Study of Bevacizumab Combined With Capecitabine and Oxaliplatin (CAPOX) in Patients With Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater.

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Mar 2018

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Oxaliplatin (Primary)
  • Indications Biliary cancer; Intestinal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Mar 2018 Status changed from active, no longer recruiting to completed.
    • 24 Feb 2017 Planned primary completion date changed from 1 May 2017 to 1 May 2018.
    • 14 Nov 2016 Results assessing safety and efficacy published in the Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top